Two Ark Invest ETFs added Tempus AI stock to their holdings last Friday. A BTIG analyst sees significant upside to Tempus AI stock. Growth investors shouldn't dismiss Tempus AI stock solely based on ...

Tempus AI has pulled back with the broader AI sector, presenting a renewed buying opportunity after strong Q3 results. TEM's Q3 sales surged 85% to $334 million, largely driven by the Ambry ...

Tempus AI (TEM) delivered 90% revenue growth in Q2 to $314.6M, driven by 115% genomics growth and 36% Data and Insights expansion. Tempus raised full-year 2025 revenue guidance to $1.26B and ...

Tempus AI specializes in developing artificial intelligence solutions to improve patient outcomes in various healthcare fields. Ark Invest reduced the Tempus AI position in the ARK Innovation ETF.

Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...

Paige’s strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Tempus Resources Ltd. ( ...

CANADA - 2025/04/23: In this photo illustration, the Tempus AI logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) AstraZeneca ...

Human resources giant Workday has disclosed a data breach after attackers gained access to a third-party customer relationship management (CRM) platform in a recent social engineering attack.

Proofpoint observed campaigns impersonating trusted brands like SharePoint and DocuSign with malicious OAuth applications to get into Microsoft 365 accounts. Threat actors have cooked up a clever way ...